A Promising New Combo for a Rare Uterine Cancer
A Promising New Combo for a Rare Uterine Cancer
Hello. I am Dr. Maurie Markman from the University of Texas MD Anderson Cancer Center. I want to briefly discuss a very interesting paper that appeared in the June 1, 2010 issue of the Journal of Clinical Oncology entitled "Phase 2 Evaluation in Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study." This is an uncommon malignancy but one that has been difficult to know how to treat because it hasn't been clear whether the focus should be on managing this as a sarcoma or as an epithelial malignancy (eg, the way we treat ovarian cancer or adenocarcinoma of the uterus.)
In this study, 55 patients with a diagnosis of carcinosarcoma of the uterus were treated, and the Gynecologic Oncology Group observed a 54% overall response rate, including a 13% complete response rate. Clearly, the combination of carboplatin and paclitaxel is active in patients with carcinosarcoma of the uterus; and, as noted in this article, the next step will be to conduct a randomized phase 3 trial directly comparing carboplatin and paclitaxel with what is often considered to be standard care -- a regimen of ifosfamide plus paclitaxel. I would encourage you to read this paper in the Journal of Clinical Oncology, and I think that this information is relevant in considering management of patients with advanced metastatic or recurrent carcinosarcoma of the uterus.
Thank you for your attention.
Hello. I am Dr. Maurie Markman from the University of Texas MD Anderson Cancer Center. I want to briefly discuss a very interesting paper that appeared in the June 1, 2010 issue of the Journal of Clinical Oncology entitled "Phase 2 Evaluation in Paclitaxel and Carboplatin in the Treatment of Carcinosarcoma of the Uterus: A Gynecologic Oncology Group Study." This is an uncommon malignancy but one that has been difficult to know how to treat because it hasn't been clear whether the focus should be on managing this as a sarcoma or as an epithelial malignancy (eg, the way we treat ovarian cancer or adenocarcinoma of the uterus.)
In this study, 55 patients with a diagnosis of carcinosarcoma of the uterus were treated, and the Gynecologic Oncology Group observed a 54% overall response rate, including a 13% complete response rate. Clearly, the combination of carboplatin and paclitaxel is active in patients with carcinosarcoma of the uterus; and, as noted in this article, the next step will be to conduct a randomized phase 3 trial directly comparing carboplatin and paclitaxel with what is often considered to be standard care -- a regimen of ifosfamide plus paclitaxel. I would encourage you to read this paper in the Journal of Clinical Oncology, and I think that this information is relevant in considering management of patients with advanced metastatic or recurrent carcinosarcoma of the uterus.
Thank you for your attention.
Source...